Indian Patent Office rejects Sovaldi patent, paves way for generics

16-01-2015

Indian Patent Office rejects Sovaldi patent, paves way for generics

Spectral-Design / Shutterstock.com

The Indian Patent Office (IPO) has rejected one of US drug maker Gilead’s patent applications to cover hepatitis C drug Sovaldi (sofosbuvir), in a decision that may decrease the blockbuster’s cost in the country.


Sovaldi, Gilead, Indian Patent Office, sofosbuvir, section 3(d)

LSIPR